- Home
- SUJA vs CCCC Comparison
SUJA vs CCCC Comparison
Compare SUJA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUJA | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 404.7M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUJA | CCCC |
|---|---|---|
| Price | $9.33 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 916.2K | ★ 2.3M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $5.59 | $1.69 |
| 52 Week High | $11.93 | $5.17 |
Technical Indicators
Market Signals| Indicator | SUJA | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 58.78 |
| Support Level | $8.83 | $3.40 |
| Resistance Level | $11.04 | $4.60 |
| Average True Range (ATR) | 0.69 | 0.23 |
| MACD | 0.30 | 0.03 |
| Stochastic Oscillator | 97.57 | 74.21 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.